Golden State Equity Partners Sells 704 Shares of Hologic, Inc. (NASDAQ:HOLX)

Golden State Equity Partners decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,933 shares of the medical equipment provider’s stock after selling 704 shares during the quarter. Golden State Equity Partners’ holdings in Hologic were worth $211,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of HOLX. Creative Planning boosted its stake in Hologic by 2.4% during the 2nd quarter. Creative Planning now owns 21,813 shares of the medical equipment provider’s stock worth $1,620,000 after acquiring an additional 503 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Hologic in the second quarter valued at approximately $1,212,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Hologic in the second quarter valued at approximately $100,000. Czech National Bank lifted its stake in Hologic by 6.4% in the third quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider’s stock valued at $3,854,000 after buying an additional 2,843 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX stock opened at $71.58 on Wednesday. The company has a market cap of $16.16 billion, a price-to-earnings ratio of 21.50, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98. Hologic, Inc. has a 52 week low of $68.61 and a 52 week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $73.05 and a 200-day moving average of $77.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the firm posted $0.89 EPS. Hologic’s revenue was up 4.5% compared to the same quarter last year. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of research reports. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Monday. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $88.92.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.